An Updated Economic Analysis Of Treatment Costs Related To Parenteral Nutrition

Published May 12, 2014
Deerfield, IL, USA - Patients with dysfunctional gastrointestinal tracts receive parenteral nutrition (PN) to help meet their nutrition requirements. Parenteral nutrition may be administered through a variety of techniques including premixed or pharmacy compounded solutions. The decision about PN delivery choice can be complex and there are no specific guidelines advising an optimal method. Researchers at Baxter Healthcare Corporation and Premier Research Services sought to build on published evidence through a retrospective analysis of Premier’s Hospital Database by comparing outcomes in critically ill adult patients receiving premixed versus compounded PN. Specifically, they compared patients’ total health care costs, length of hospital stay, infectious complications, and hospital readmission rates. After adjusting for confounding variables, they found patients receiving premixed PN incurred nine percent less in total costs, 2.6 percent fewer days in the hospital, and no significant differences for infectious complications or 30-day readmission. This study aimed to provide a more comprehensive PN economic analysis than previous evaluations. The researchers noted that, excluding overall costs, patients experienced similar outcomes irrespective of the PN preparation delivery chosen, therefore, future studies need to further explore cost drivers. Study lead, Gary Zaloga, MD, Senior Medical Director at Baxter, states, “Given this information, clinicians should continue to focus on best practices that will lead to improve patient outcomes and a reduction in financial burden.” The full study, “A Retrospective, Observational Study of Patient Outcomes for Critically Ill Patients Receiving Parenteral Nutrition,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×